Tyra Biosciences reported a higher net loss for the fourth quarter and full year 2025, while simultaneously advancing its dabogratinib 3×3 clinical strategy and bolstering its leadership team. This combination of deeper losses and intensified late-stage development around dabogratinib in FGFR3-driven diseases is sharpening investor focus on the company’s precision oncology and rare disease ambitions. We will now examine how Tyra’s dabogratinib 3×3 strategy and recent clinical progress shape…